In this review, we present the evidence supporting the use of a dual GIP/GLP-1 receptor agonist in the treatment of obesity, highlighting the physiological mechanisms and discussing the preclinical and clinical trials of this drug. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.